- Home
- LFT vs NRXS Comparison
LFT vs NRXS Comparison
Compare LFT & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LFT | NRXS |
|---|---|---|
| Founded | 2012 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.1M | 78.9M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | LFT | NRXS |
|---|---|---|
| Price | $1.14 | $8.05 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | 110.5K | ★ 190.6K |
| Earning Date | 05-13-2026 | 05-12-2026 |
| Dividend Yield | ★ 18.49% | N/A |
| EPS Growth | N/A | ★ 22.13 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,569,282.00 |
| Revenue This Year | $668.15 | $172.91 |
| Revenue Next Year | N/A | $115.71 |
| P/E Ratio | $13.49 | ★ N/A |
| Revenue Growth | N/A | ★ 32.89 |
| 52 Week Low | $1.12 | $2.20 |
| 52 Week High | $2.65 | $9.33 |
Technical Indicators
Market Signals| Indicator | LFT | NRXS |
|---|---|---|
| Relative Strength Index (RSI) | 30.83 | 56.90 |
| Support Level | N/A | $6.92 |
| Resistance Level | $1.40 | $9.33 |
| Average True Range (ATR) | 0.04 | 0.69 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 11.11 | 46.30 |
Price Performance
Historical ComparisonAbout LFT Lument Finance Trust Inc.
Lument Finance Trust Inc operates as a real estate investment trust. The company is engaged in investment, financing, and management of a portfolio of commercial real estate debt investments. It invests in transitional floating-rate commercial real estate mortgage loans, mezzanine loans, preferred equity, commercial mortgage-backed securities, fixed-rate loans, construction loans, and other CRE debt instruments.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).